Nuvectis Pharma earnings date
Want to see NVCT full AI Analyst Report?
Nuvectis Pharma (NVCT) Q3 2026 Earnings Report
NVCT Q3 2026 EPS Results
- Actual EPS
- -$1.02
- Consensus EPS
- -$0.24
- Beat/Miss
- Missed by -$0.78
- One Year Ago EPS
- -$0.44
NVCT Q3 2026 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- Before Open
- Conference Call
- Wednesday, November 4, 2026
Nuvectis Pharma's next earnings date is estimated for March 9, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, driven by the transformation into a late-stage development company, the China approval of NXP-100, encouraging NXP-100 and NXP-200 clinical data, substantial financing, and a cash runway into the second half of 2029. The primary challenges were the reported quarterly net loss, the unresolved FDA requirements for U.S. PNH development, and the need for additional NXP-200 solid tumor data, but these issues were outweighed by the number and significance of the stated achievements and upcoming catalysts.
Management expects approximately $140 million in cash to fund operations into the second half of 2029 and beyond multiple value inflection points; it expects an update on the FDA interaction for NXP-100 by year end, approval in China for previously treated PNH patients in the first quarter of 27, an IND for another indication outside of PNH later this year, clinical trials in additional indications in the first half of 27, a US IND for NXP-200 by the end of the year and a US phase 1 b in early 27, additional NXP-200 phase 1b data in early 27, and NXP-900 clinical updates in the first half of 27; for NXP-100, the company’s goal is to file at least 1 IND by the end of the year and be in a position to start clinical trials as soon as possible in 2027, while NXP-200 may have as many as 15 to 17 patients in the BRAF relapse subset, with a 20 percent or 25 percent response rate considered success.
- Transformation into a Late-Stage Development CompanyManagement said the third quarter was transformational, with Nuvectis adding two late-stage drug candidates through an ex-China licensing agreement with Haisco: NXP-100 (ciprocfeltin) and NXP-200. The company said the additions fundamentally changed its opportunity ahead.
- Strong Financing and Cash RunwayFollowing the Haisco licensing agreement, Nuvectis completed a follow-on offering generating $150 million in gross proceeds and placed approximately $37 million with a single healthcare-dedicated fund through its ATM facility. The company ended the quarter with approximately $140 million in cash and expects this to fund operations into the second half of 2029 and beyond multiple value inflection points.
- NXP-100 Received First China Marketing ApprovalIn July, NXP-100 received its first marketing approval in China for newly diagnosed PNH patients who had not previously received complement inhibitors. The approval was based on a Phase 3 study in which NXP-100 demonstrated superiority versus Soliris on the primary and all key secondary endpoints.
- Additional China PNH Approval Under ReviewA second marketing application for NXP-100 in China, covering PNH patients previously treated with C5 inhibitors, is under review. The application is supported by another Phase 3 study that met its primary and key secondary endpoints, and Haisco is expected to announce a decision in the first quarter of 2027.
- Robust Hemoglobin Improvements in PNH StudiesAcross the Phase 3 studies, NXP-100 produced average hemoglobin increases of 5 grams per deciliter in treatment-naive patients and 4.4 grams per deciliter in previously treated patients. Management described the overall hemoglobin increase as unprecedented and said the safety profile appeared consistent with other complement inhibitors.
- NXP-100 IgA Nephropathy Data and Ongoing Phase 3Following a successful 24-week Phase 2 study in IgA nephropathy, NXP-100 demonstrated a statistically and clinically meaningful reduction in proteinuria, including a 57% proteinuria reduction, and an almost 3-point eGFR increase versus a 1.5-point decline in the placebo arm. A fully powered 370-patient Phase 3 study is ongoing in China, with a one-year treatment horizon and one-year follow-up; data are expected around April or May.
- Once-Daily Oral Dosing Advantage for NXP-100NXP-100 is an oral Factor B inhibitor administered once daily, compared with twice-daily dosing for Novartis' FABALTA. Management emphasized the potential convenience advantage for chronic, lifelong treatment such as PNH and said the PNH and IgA nephropathy markets together are estimated to exceed $20 billion within the next 10 years.
- Expansion Opportunities for NXP-100Nuvectis plans to submit at least one IND for NXP-100 by the end of 2026 and start additional clinical trials as soon as possible in 2027. Potential areas discussed included IgA nephropathy, C3G, PNH and other hematology indications. The company also plans to initiate clinical trials in additional indications in the first half of 2027.
- Constructive FDA Dialogue for U.S. PNH DevelopmentManagement said its FDA discussions regarding the U.S. PNH development plan are going well, described the FDA as very engaged, and expects to provide an update on the U.S. regulatory path by year-end. Nuvectis said it believes the two positive China Phase 3 studies provide a strong clinical data package.
- NXP-200 Received Breakthrough Designation in ChinaIn September, NXP-200 received breakthrough designation in China for BRAF V600 mutant recurrent or progressive high-grade glioma. Nuvectis remains on track to submit a U.S. IND by the end of 2026, with the goal of starting a U.S. Phase 1b study in early 2027.
- Positive NXP-200 Glioma ActivityIn a 27-patient Phase 1b study presented at ESMO, NXP-200 showed a 40% objective response rate in the high-grade glioma cohort of 20 patients, including three complete responses, two confirmed and one pending. The low-grade glioma cohort had a 42.9% objective response rate, including one confirmed complete response. Responses were assessed using RANO 2.0 criteria.
- NXP-200 Activity After Prior BRAF TreatmentNXP-200 generated responses in two of three patients who had previously been exposed to a BRAF inhibitor. Management identified activity in previously treated patients as a potential differentiator and said the drug demonstrated deep and durable single-agent activity, including complete responses in recurrent or progressive gliomas.
- NXP-200 Solid Tumor Expansion PotentialManagement said durable responses in non-small cell lung cancer, colorectal cancer and papillary thyroid cancer support development across a broad range of solid tumors. An update from the ongoing Phase 1b study in China is expected within the next two to three months, including a possible update on approximately 15 to 17 BRAF-relapsed patients. Management said a 20% to 25% response rate in that setting would constitute success.
- NXP-900 Combination Studies ContinueThe Phase 1b program for the legacy oncology candidate NXP-900 continues, including combination studies with osimertinib and lorlatinib. A planned investigator-initiated study will evaluate NXP-900 with the newly approved KRAS inhibitor sotorasib in pancreatic cancer, led by two top medical centers. Further clinical updates are expected in the first half of 2027.
- Complement Program Expansion and Manufacturing PreparationNuvectis hired Dr. Dustin Little as senior vice president and head of the complement program. Dr. Little brings physician-scientist and nephrology experience, including a decade at AstraZeneca. The company is also conducting technology transfer to move manufacturing of NXP-100 and NXP-200 to its CMO over time, while stating that this will not slow the start of clinical trials.
- Multiple Near-Term CatalystsExpected catalysts include a year-end update on the U.S. PNH regulatory path, at least one NXP-100 IND filing by year-end, potential China approval for previously treated PNH patients in the first quarter of 2027, NXP-200 U.S. IND filing by year-end, additional NXP-200 solid tumor data in early 2027, and NXP-900 clinical updates in the first half of 2027.
- Validated Commercial Opportunity in Complement and BRAFManagement said the PNH market is estimated at approximately $5 billion today and expected to double within eight to 10 years. FABALTA, the only FDA-approved Factor B inhibitor cited, has reached an annualized run rate of approximately $1 billion about two years after launch. Management also said first-generation BRAF inhibitors generate more than $4 billion in combined annual revenue.
NVCT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 09, 2027 | 2026 (Q4) | -0.37- | -0.31 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.24-1.02 | -0.44 | -131.82% (-0.58) | |
| Aug 04, 2026 | 2026 (Q2) | -0.26-0.30 | -0.3 | 0.00% (+0.00) | |
| May 05, 2026 | 2026 (Q1) | -0.31-0.26 | -0.27 | 3.70% (+0.01) | |
| Feb 11, 2026 | 2025 (Q4) | -0.32-0.31 | -0.35 | 11.43% (+0.04) | |
| Nov 04, 2025 | 2025 (Q3) | -0.25-0.44 | -0.24 | -83.33% (-0.20) | |
| Aug 05, 2025 | 2025 (Q2) | -0.25-0.30 | -0.26 | -15.38% (-0.04) | |
| May 06, 2025 | 2025 (Q1) | -0.25-0.27 | -0.25 | -8.00% (-0.02) | |
| Feb 25, 2025 | 2024 (Q4) | -0.25-0.35 | -0.41 | 14.63% (+0.06) | |
| Nov 05, 2024 | 2024 (Q3) | -0.25-0.24 | -0.37 | 35.14% (+0.13) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

